This Brown & Brown Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Comments
Loading...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

  • Morgan Stanley analyst Bob Huang downgraded the rating for Brown & Brown, Inc. BRO from Overweight to Equal-Weight and maintained the price target of $128. Brown & Brown shares closed at $120.98 on Monday. See how other analysts view this stock.
  • Jefferies analyst Surinder Thind downgraded Dun & Bradstreet Holdings, Inc. DNB from Buy to Hold and cut the price target from $11 to $9.15. Dun & Bradstreet shares closed at $8.99 on Monday. See how other analysts view this stock.
  • Leerink Partners analyst Marc Goodman downgraded Opthea Limited OPT from Outperform to Market Perform and lowered the price target from $12 to $1. Opthea shares closed at $3.36 on Monday. See how other analysts view this stock.
  • Citigroup analyst Anthony Pettinari downgraded the rating for The AZEK Company Inc. AZEK from Buy to Neutral and lowered the price target from $61 to $51.5. AZEK shares closed at $48.56 on Monday. See how other analysts view this stock.
  • Stephens & Co. analyst Mason Carrico downgraded Akoya Biosciences, Inc. AKYA from Overweight to Equal-Weight and slashed the price target from $3.5 to $1.8. Akoya Biosciences shares closed at $1.67 on Monday.  See how other analysts view this stock.

Considering buying BRO stock? Here’s what analysts think:

Read This Next:

AKYA Logo
AKYAAkoya Biosciences Inc
$1.2510.2%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
5.12
Growth
20.72
Quality
-
Value
29.38
Price Trend
Short
Medium
Long
Got Questions? Ask
Which insurance stocks may be undervalued now?
How will Dun & Bradstreet's downgrade impact its competitors?
Are there alternative analytics firms to consider?
What implications does Opthea's downgrade have on biotech investments?
Could AZEK's downgrade signal a market shift in building materials?
Which construction companies could benefit from AZEK's performance?
How might Akoya Biosciences's downgrade affect biotech funding?
What investment strategies should be applied following these downgrades?
Which emerging companies might fill gaps left by these downgrades?
How will analyst ratings impact market sentiment in the coming weeks?
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm

Posted In: